Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Plasmid DNA Manufacturing Market: By Disease, By Grade, By Development Phase, By Application, and Region Forecast 2020-2031
Plasmid DNA Manufacturing Market size was valued at US$ 1,150 million in 2024 and is expected to reach US$ 2,780 million by 2031, growing at a significant CAGR of 13.5% from 2025-2031. Moreover, the U.S. Plasmid DNA Manufacturing Market is projected to grow significantly, reaching an estimated value of US$ 1,050 million by 2031. The market refers to the sector focused on the large-scale production of plasmid DNA- small, circular, double-stranded DNA molecules widely used as vectors in genetic engineering, gene therapy, DNA vaccines, and cell therapy applications. This market encompasses contract development and manufacturing organizations (CDMOs), specialized biotechnology companies, and in-house production facilities that supply high-quality, research-grade, and clinical-grade plasmid DNA. The market involves various processes such as fermentation, purification, and quality control to ensure plasmid DNA meets strict regulatory and safety standards for therapeutic and research use.
The market has experienced significant growth in recent years, driven by the expanding demand for advanced gene therapies, mRNA vaccines, and cell-based therapies. As plasmid DNA is a critical starting material for viral vector production and next-generation therapeutics, its importance in the biopharmaceutical supply chain has increased substantially. Continuous advancements in molecular biology techniques and the rising adoption of personalized medicine further boost market expansion. Additionally, growing investment in research and development, coupled with favorable regulatory support for gene and cell therapies, has strengthened market growth worldwide. Despite challenges related to production scalability and stringent quality requirements, the market is expected to continue its robust trajectory through 2031.
Based on the disease:
Cancer is the most dynamic of the disease categories for plasmid DNA manufacturing, fueled by the gene-based immunotherapy and oncolytic viral platform explosion. Plasmids serve as the template for both therapeutic cargoes and viral vectors encoding them, enabling highly bespoke, genetically encoded therapies. Whether applied to facilitate CAR-T constructs, tumor-associated antigen expression or designed immune modulation, plasmid DNA is written at every stage of cancer therapy development. The oncology pipeline is stacked with clinical-stage studies that rely on scalable, regulatory-grade manufacture of plasmids. As therapeutic treatment continues to become more personalized and modular, the accuracy and versatility of plasmid DNA production is facilitating cancer therapy in abandoning standardized treatment procedures in favor of genetically individualized treatments specific to the patient.
Based on the Grade:
R&D grade plasmid DNA remains the leading choice for early-stage therapeutic development, as the material of preference for proof-of-concept research in vaccine, gene therapy, and antibody drug development. Economical scalability and accommodating regulatory compliance make it a top choice for high-speed prototyping across multiple biologics platforms. For the development of viral vectors, R&D grade plasmids are a requirement for the production of constructs applied during transfection and packaging, particularly for lentivirus and AAV-based systems. The increased requirement for research-grade plasmids is further propelled by the rapid expansion of synthetic biology start-ups and academia collaborations prioritizing speed, iteration, and innovation over adherence to GMP-level standards. While R&D grade is the leader in plasmid design and manufacturing feasibility testing is the next-generation therapeutics ecosystem expands,
Based on the development phase:
Plasmid DNA manufacture at the clinical stage is a growth area with increasing numbers of IND-stage gene therapies, DNA vaccines, and cell-engineered immunotherapies. For this stage, there is a requirement for higher-quality parameters such as high identity, high purity, and lower endotoxin limits to satisfy regulatory needs at the expense of production scalability. Developers use clinical-grade plasmids as the main raw material to serve as the crucial raw material for viral vector production or as loads in the case of direct loads in therapeutic delivery. Larger Phase I and II trials worldwide, particularly for oncology and infectious diseases, are fueling demand for sophisticated CDMOs capable of executing mid-volume, clinical-grade manufacturing. These plasmids represent a critical bridge, translating R&D momentum into confirmed clinical success, which serves as the foundation for subsequent commercialization.
Based on the application:
Applications of cell and gene therapy have pushed plasmid DNA manufacturing to be a strategic cornerstone of next-generation medicine. Plasmids are critical templates for the construction of viral vectors, and as therapeutic products in themselves in some non-viral delivery formats. With increasing regulatory faith in gene therapies, so does the complexity and scope of plasmid construct utilise in production. The CAR-T, gene editing, and engineered stem cell platform mania has driven sustained demand for high-fidelity, customised plasmid systems. Developers now need high-performing, contamination-free lines of production capable of handling intricate promoter designs and multi-cassette systems. Here in the rapidly evolving clinical environment, plasmid DNA is no longer a stationary raw material, it's an addressable therapy at the forefront of therapeutic development and delivery.
Study Period
2024 - 2030Base Year
2024CAGR
13.5%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
A key driver propelling the market is the rising demand for gene and cell therapies worldwide. Plasmid DNA serves as a crucial starting material for producing viral vectors, which are used to deliver therapeutic genes in gene therapy, and for engineering cells in cell-based treatments such as CAR-T therapies. As more genetic diseases, cancers, and rare disorders are targeted through these advanced therapies, the need for high-quality, clinical-grade plasmid DNA has surged significantly.
Regulatory approvals of novel gene therapies and increasing clinical trial activity have further intensified this demand. Pharmaceutical and biotech companies are heavily investing in the development of personalized and precision medicines, which rely on plasmid DNA as a foundational component. This trend not only fuels the expansion of manufacturing capacity but also encourages innovation in purification and yield optimization technologies. Consequently, the plasmid DNA manufacturing market is experiencing strong, sustained growth worldwide.
Despite robust growth potential, the Global Plasmid DNA Manufacturing Market faces significant restraints due to the complexity of production processes and stringent regulatory requirements. Manufacturing plasmid DNA at a commercial scale involves multiple steps, including large-scale fermentation, intricate purification protocols, and rigorous quality control measures to ensure purity, sterility, and efficacy. These processes require substantial technical expertise, specialized equipment, and compliance with Good Manufacturing Practices (GMP) standards, which increase operational costs and time-to-market.
Moreover, regulatory agencies impose strict guidelines on the production of plasmid DNA intended for clinical use to safeguard patient safety, often leading to lengthy approval and validation processes. Any deviation or contamination can result in batch failures, financial losses, and supply delays. These factors create barriers, particularly for smaller biotech firms and new market entrants, limiting their ability to scale operations rapidly. Addressing these manufacturing and compliance challenges remains essential for sustaining market momentum and ensuring reliable supply.
A significant opportunity in the market lies in the expansion of mRNA and DNA vaccine platforms. The success of mRNA vaccines during the COVID-19 pandemic demonstrated the potential of nucleic acid-based vaccines to be developed and scaled rapidly. Plasmid DNA is a vital template for in vitro transcription of mRNA and is directly used in DNA vaccines, positioning it as a critical component in future pandemic preparedness and infectious disease control strategies. As researchers explore vaccine candidates for various viral and bacterial infections, as well as for cancer immunotherapy, the demand for plasmid DNA is expected to grow exponentially.
Governments and international health organizations are actively investing in building manufacturing infrastructure to ensure rapid vaccine availability in the event of emerging infectious diseases. This strong focus on vaccine innovation and preparedness offers plasmid DNA manufacturers opportunities to expand their capacity, form strategic partnerships, and enter new therapeutic markets globally.
A prominent trend shaping the market is the increasing reliance on contract development and manufacturing organizations (CDMOs) for plasmid DNA production. As gene and cell therapy pipelines expand, many pharmaceutical and biotechnology companies are choosing to outsource plasmid DNA manufacturing to specialized CDMOs rather than investing in in-house capabilities. This trend allows companies to focus on core R&D and commercialization activities while leveraging the technical expertise, advanced infrastructure, and regulatory know-how of experienced CDMOs.
Additionally, outsourcing offers scalability and flexibility to meet fluctuating demand, particularly during clinical trial phases or rapid market launches. CDMOs are responding by expanding their GMP-compliant facilities, adopting automation technologies, and integrating advanced quality assurance systems to ensure high standards. This shift is fostering a more competitive, service-driven landscape and is expected to drive further investments and consolidation in the plasmid DNA manufacturing sector over the coming years.
Report Benchmarks |
Details |
Report Study Period |
2024 - 2030 |
Market Size in 2024 |
US$ 1,150 million |
Market Size in 2031 |
US$ 2,780 million |
Market CAGR |
13.5% |
By Disease |
|
By Grade |
|
By Deployment Phase |
|
By Application |
|
By Region |
|
According to PBI Analyst, the market is shifting from a specialized backend process to a core enabler of next-generation therapies. As gene and cell therapy pipelines expand, plasmid DNA has become foundational for viral vector production, DNA vaccines, and gene editing technologies. Developers are under pressure to meet rising clinical-grade standards, while CDMOs are building vertically integrated, contamination-free platforms to reduce time-to-clinic. Regulatory momentum around antibiotic-free systems and automated manufacturing lines is transforming production expectations. North America leads due to mature infrastructure, while Asia-Pacific is accelerating through biotech funding and domestic GMP capabilities. The market’s future will hinge on scalability, regulatory adaptability, and rapid therapeutic translation.
Download Free Sample Report
The plasmid DNA manufacturing market size was valued at US$ 1,150 million in 2024 and is projected to grow at a significant CAGR of 13.5% from 2025-2031.
Asia-pacific is the fastest growing region for market.
The primary driver is the increasing demand for plasmid DNA in gene therapies, DNA vaccines, and immunotherapies, transitioning it from a lab reagent to a critical manufacturing feedstock.
The most defining trend is the shift towards high-yield, antibiotic-free plasmid systems that reduce compliance risks and improve downstream process efficiency.
Market research is segmented based on disease, grade, development phase, application, and region.
1.Executive Summary |
2.Global Plasmid DNA Manufacturing Market Introduction |
2.1.Global Plasmid DNA Manufacturing Market - Taxonomy |
2.2.Global Plasmid DNA Manufacturing Market - Definitions |
2.2.1.Disease |
2.2.2.Grade |
2.2.3.Deployment Phase |
2.2.4.Application |
2.2.5.Region |
3.Global Plasmid DNA Manufacturing Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Plasmid DNA Manufacturing Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Plasmid DNA Manufacturing Market By Disease, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
5.1. Infectious Disease |
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Cancer |
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Genetic Disorder |
5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Others |
5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6.Global Plasmid DNA Manufacturing Market By Grade, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
6.1. R&D Grade |
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. GMP Grade |
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7.Global Plasmid DNA Manufacturing Market By Deployment Phase, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
7.1. Pre-Clinical Therapeutics |
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Clinical Therapeutics |
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Marketed Therapeutics |
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Plasmid DNA Manufacturing Market By Application, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
8.1. DNA Vaccines |
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Cell & Gene Therapy |
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Immunotherapy |
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Others |
8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
9.Global Plasmid DNA Manufacturing Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10.North America Plasmid DNA Manufacturing Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
10.1. Disease Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Infectious Disease |
10.1.2.Cancer |
10.1.3.Genetic Disorder |
10.1.4.Others |
10.2. Grade Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.R&D Grade |
10.2.2.GMP Grade |
10.3. Deployment Phase Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Pre-Clinical Therapeutics |
10.3.2.Clinical Therapeutics |
10.3.3.Marketed Therapeutics |
10.4. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.DNA Vaccines |
10.4.2.Cell & Gene Therapy |
10.4.3.Immunotherapy |
10.4.4.Others |
10.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11.Europe Plasmid DNA Manufacturing Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
11.1. Disease Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Infectious Disease |
11.1.2.Cancer |
11.1.3.Genetic Disorder |
11.1.4.Others |
11.2. Grade Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.R&D Grade |
11.2.2.GMP Grade |
11.3. Deployment Phase Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Pre-Clinical Therapeutics |
11.3.2.Clinical Therapeutics |
11.3.3.Marketed Therapeutics |
11.4. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.DNA Vaccines |
11.4.2.Cell & Gene Therapy |
11.4.3.Immunotherapy |
11.4.4.Others |
11.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
12.Asia Pacific (APAC) Plasmid DNA Manufacturing Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
12.1. Disease Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Infectious Disease |
12.1.2.Cancer |
12.1.3.Genetic Disorder |
12.1.4.Others |
12.2. Grade Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.R&D Grade |
12.2.2.GMP Grade |
12.3. Deployment Phase Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Pre-Clinical Therapeutics |
12.3.2.Clinical Therapeutics |
12.3.3.Marketed Therapeutics |
12.4. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.DNA Vaccines |
12.4.2.Cell & Gene Therapy |
12.4.3.Immunotherapy |
12.4.4.Others |
12.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13.Middle East and Africa (MEA) Plasmid DNA Manufacturing Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
13.1. Disease Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Infectious Disease |
13.1.2.Cancer |
13.1.3.Genetic Disorder |
13.1.4.Others |
13.2. Grade Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.R&D Grade |
13.2.2.GMP Grade |
13.3. Deployment Phase Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Pre-Clinical Therapeutics |
13.3.2.Clinical Therapeutics |
13.3.3.Marketed Therapeutics |
13.4. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.DNA Vaccines |
13.4.2.Cell & Gene Therapy |
13.4.3.Immunotherapy |
13.4.4.Others |
13.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14.Latin America Plasmid DNA Manufacturing Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
14.1. Disease Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Infectious Disease |
14.1.2.Cancer |
14.1.3.Genetic Disorder |
14.1.4.Others |
14.2. Grade Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.R&D Grade |
14.2.2.GMP Grade |
14.3. Deployment Phase Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Pre-Clinical Therapeutics |
14.3.2.Clinical Therapeutics |
14.3.3.Marketed Therapeutics |
14.4. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.DNA Vaccines |
14.4.2.Cell & Gene Therapy |
14.4.3.Immunotherapy |
14.4.4.Others |
14.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.Charles River Laboratories |
15.2.2.VGXI, Inc. |
15.2.3.Danaher (Aldevron) |
15.2.4.Kaneka Corp. |
15.2.5.Nature Technology |
15.2.6.Cell and Gene Therapy Catapult |
15.2.7.Eurofins Genomics |
15.2.8.Lonza |
15.2.9.Luminous BioSciences, LLC |
15.2.10.Akron Biotech |
16. Research Methodology |
17. Appendix and Abbreviations |
Key Market Players